Gonadotropin-releasing hormone antagonist: how good is the new hope?

Albano C, C Albano, Platteau P, P Platteau, Devroey P, P. Devroey
Current opinion in obstetrics & gynecology · 2001 · doi:10.1097/00001703-200106000-00002 · PMID:11396647
review OA: closed public-domain-us
Full text JSON View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-08-25 ⓘ

This paper reviews gonadotropin-releasing hormone antagonists as an alternative to agonists for treating endometriosis and uterine myoma, noting their immediate inhibition of gonadotropin secretion and the need for further comparative studies.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-08-24 · read from full text ⓘ

This review compares gonadotropin-releasing hormone (GnRH) antagonists with agonists, highlighting that antagonists provide immediate inhibition of gonadotropin secretion by competitively blocking pituitary receptors. While GnRH agonists require a two-to-three-week lag period for pituitary desensitization due to an initial stimulatory effect, antagonists avoid this delay and have demonstrated advantages in controlled ovarian stimulation. The authors note that although antagonists show promise for treating uterine myoma and endometriosis, randomized comparative studies are still needed to fully establish their benefits over agonists for these conditions. Relevance to endometriosis: listed as one indication for GnRH antagonists, though the paper's main focus is uterine fibroids.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Gonadotropin-releasing hormone agonists have been widely used to prevent luteinizing hormone surges during controlled ovarian stimulation in assisted reproductive technologies. Treatment with gonadotropin-releasing hormone agonists of uterine myoma, endometriosis and some hormone-dependent cancers, such as breast, ovarian, endometrial and prostate cancer, also seems to have a beneficial effect. Gonadotropin-releasing hormone agonists have the disadvantage of inducing an initial stimulatory effect on gonadotropin secretion, necessitating 2-3 weeks before pituitary desensitization is achieved. Gonadotropin-releasing hormone antagonists, on the contrary, cause an immediate inhibition of gonadotropin secretion by competitive blocking of pituitary gonadotropin-releasing hormone receptors. Some advantages of their clinical use in controlled ovarian stimulation have already been demonstrated. Randomized comparative studies are needed to investigate their benefit over gonadotropin-releasing hormone antagonists for myoma and hormone-related disorders.
Full text 1,175 characters · extracted from oa-doi-fallback · click to expand
Gonadotropin-releasing hormone antagonist: how good is the new hope? - Carola Albano - Peter Platteau - Paul Devroey Gonadotropin-releasing hormone agonists have been widely used to prevent luteinizing hormone surges during controlled ovarian stimulation in assisted reproductive technologies. Treatment with gonadotropin-releasing hormone agonists of uterine myoma, endometriosis and some hormone-dependent cancers, such as breast, ovarian, endometrial and prostate cancer, also seems to have a beneficial effect. Gonadotropin-releasing hormone agonists have the disadvantage of inducing an initial stimulatory effect on gonadotropin secretion, necessitating 2-3 weeks before pituitary desensitization is achieved. Gonadotropin-releasing hormone antagonists, on the contrary, cause an immediate inhibition of gonadotropin secretion by competitive blocking of pituitary gonadotropin-releasing hormone receptors. Some advantages of their clinical use in controlled ovarian stimulation have already been demonstrated. Randomized comparative studies are needed to investigate their benefit over gonadotropin-releasing hormone antagonists for myoma and hormone-related disorders.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

MeSH descriptors

Gonadotropin-Releasing Hormone Gonadotropin-Releasing Hormone Infertility, Female Female Gonadotropin-Releasing Hormone Gonadotropins Gonadotropins Humans Infertility, Female Neoplasms, Hormone-Dependent Neoplasms, Hormone-Dependent Receptors, Gonadotropin Receptors, Gonadotropin

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-09-17T06:16:55.786923+00:00
pubmed
last seen: 2026-05-13T22:13:24.901228+00:00
unpaywall
last seen: 2026-05-14T19:30:52.867331+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine